Back to top

Truist Financial Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on NewAmsterdam Pharma Company, with a price target ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

NewAmsterdam Pharma Company N.V. (NAMS)